IDEMIA
3.6.2019 10:05:10 CEST | Business Wire | Press release
Considering global market demand for independent and standardized payment solutions, G+D Mobile Security and IDEMIA announce their intention to create the White Label Alliance (WLA) to provide a new security solution for next generation payment applications. The solution will be based on White Label EMV specifications and will enable ready-to-deploy solutions for domestic payment schemes and closed-loop worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005349/en/
The new alliance is a response to the growing global demand for new, next-generation independent payment solutions. By providing global open standards that are governed by an independent body, the White Label Alliance (WLA) ensures that commercial solutions can be built on these specifications enabling innovative and competitive offerings. The White Label Alliance (WLA) aims to enable ready-to-deploy solutions for domestic payment schemes and closed-loop worldwide
The aim of the White Label Alliance (WLA) cooperation is to design and maintain an open, comprehensive and standardized framework to meet the requirements of open and closed payment systems. Based on the EMV standard, the White Label Alliance (WLA) solution ensures scalability for all technologies: for cards, terminals and mobile devices. Therefore the White Label Alliance is strongly committed to open standards to ensure additional value for the payment ecosystem.
For these reasons, the White Label Alliance (WLA) initiative encourages an ecosystem that enables innovations and competitive offerings based on a worldwide standard.
As the owner of the specifications, the White Label Alliance (WLA) will work on future-proof evolution of the solution being in line with demands of the members. In order to expand the network and to grow accessible payment schemes, the White Label Alliance (WLA) invites all interested payment stakeholders to join.
“The close cooperation of companies such as G+D Mobile Security and IDEMIA within the framework of the new alliance demonstrates the effort to define new open payment specifications that ultimately benefit all end users." explains Gabriele Bugat, Head of Financial Services Solutions at G+D Mobile Security. "We are also planning to gain more members for the new alliance later this year in order to put our plans on an even broader footing."
"Supporting open standards and delivering interoperable solutions has always been a key concern for our company. That is why we are very pleased to be part of this initiative," says Amanda Gourbault Executive Vice President for Financial Institutions activities at IDEMIA. "Based on our extensive experience in the development of EMV technology, we want to play a key role in creating an open alliance which will allow domestic payment networks, transport operators and closed loop retailers to deploy a truly independent solution based on proven technology, with a fast time to market.”
About G+D Mobile Security
G+D Mobile Security is a global mobile security technology group headquartered in Munich, Germany. The company is part of the Giesecke+Devrient Group. G+D Mobile Security has around 5,300 employees worldwide and generated sales of around 868 million euros in the 2018 financial year. More than 40 sales offices and more than 20 certified production and personalization locations worldwide ensure international customer proximity.
G+D Mobile Security manages and secures billions of digital identities over their entire lifecycle. Our products and solutions are used daily by banks, network operators, manufacturers of mobile devices and automobiles, health insurance companies, private and public transport companies and their customers to secure mobile payment, communication and interaction between devices. G+D Mobile Security holds a leading competitive and technological position in these markets. Further information can be found at https://www.gi-de.com/de/de/mobile-security
About Idemia
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel and vote), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 13,000 employees around the world, IDEMIA serves clients in 180 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005349/en/
Contact:
Christoph Lang Giesecke+Devrient press spokesman corporate communications Phone: +49 89 4119-2164 E-mail: christoph.lang@gi-de.com
IDEMIA / Havas PR agency Email: idemia@havas.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
